Source comparison
PT-141 vs Other Melanocortin Peptides: Onset Comparison
PT-141 (Bremelanotide) MC3R, MC4R 30–45 min 60–90 min 2.7 hours Fastest onset among MC4R agonists; used in sexual dysfunction and autonomic research Melanotan II (MT-II) MC1R, MC3R, MC4R, MC5R 45–60 min 90–120 min 33 minutes Broader receptor profile; more side
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- MC3R, MC4R
- 30–45 min
- 60–90 min
- 2.7 hours
- Fastest onset among MC4R agonists; used in sexual dysfunction and autonomic research
- Melanotan II (MT-II)
- MC1R, MC3R, MC4R, MC5R
- 45–60 min
- 90–120 min
- 33 minutes
- Broader receptor profile; more side effects; shorter half-life limits research utility
- Alpha-MSH (endogenous)
- 15–30 min
- <10 minutes
- Rapid onset but extremely short duration; requires continuous infusion in research
- NDP-MSH (synthetic analogue)
- 20–30 min
- 50–70 min
- 30 minutes
- Primarily used in pigmentation research; less selective than PT-141
- Setmelanotide
- MC4R (high selectivity)
- 120–180 min
- 2.5 hours
- FDA-approved for obesity; slower onset reflects higher receptor selectivity and oral bioavailability
- PT-141's intermediate half-life (2.7 hours) and MC4R selectivity make it ideal for studies requiring sustained receptor activation without the dosing frequency of shorter-acting peptides. Melanotan II, despite structural similarity, acts on MC1R (melanogenesis) and MC5R (exocrine function) more promiscuously, introducing confounding variables in autonomic or behavioural studies. Researchers studying melanocortin pathways should select peptides based on receptor specificity first, onset speed second.